Pavel, M. E., Verslype, C., Rocha, P., Greystoke, A., Chauhan, A., Koevi, J., Mueller, M., Song, E., Lifke, V., Bergsland, E. K. (2026). Obrixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): Dose expansion part of the phase II DAREON-5 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps2